Levodopa

"Levodopa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.

Descriptor ID	D007980
MeSH Number(s)	D02.092.311.200.480 D12.125.072.050.685.400.500 D12.125.072.050.875.130.500
Concept/Terms	Levodopa Levodopa L-Dopa L Dopa 3-Hydroxy-L-tyrosine 3 Hydroxy L tyrosine L-3,4-Dihydroxyphenylalanine L 3,4 Dihydroxyphenylalanine Levopa Levopa Larodopa Larodopa Dopaflex Dopaflex Dopar Dopar

Below are MeSH descriptors whose meaning is more general than "Levodopa".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Amines [D02.092]
Catecholamines [D02.092.311]
Dihydroxyphenylalanine [D02.092.311.200]
Levodopa [D02.092.311.200.480]
Amino Acids, Peptides, and Proteins [D12]
Amino Acids [D12.125]
Amino Acids, Cyclic [D12.125.072]
Amino Acids, Aromatic [D12.125.072.050]
Phenylalanine [D12.125.072.050.685]
Dihydroxyphenylalanine [D12.125.072.050.685.400]
Levodopa [D12.125.072.050.685.400.500]
Tyrosine [D12.125.072.050.875]
Dihydroxyphenylalanine [D12.125.072.050.875.130]
Levodopa [D12.125.072.050.875.130.500]

Below are MeSH descriptors whose meaning is related to "Levodopa".

Below are MeSH descriptors whose meaning is more specific than "Levodopa".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Levodopa" by people in this website by year, and whether "Levodopa" was a major or minor topic of these publications.

Bar chart showing 9 publications over 7 distinct years, with a maximum of 2 publications in 2006 and 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2003	0	1	1
2006	0	2	2
2007	1	0	1
2008	1	0	1
2013	1	1	2
2023	0	1	1
2026	0	1	1

Below are the most recent publications written about "Levodopa" by people in Profiles.

Piccinin CC, Yu JRT, Stepanyants V, Hogue O, Sonneborn C, Brooks A, Clark P, Shaffer S, Moser L, Lopez-Gonzalez T, Sokola BS, Lewin K, Popov R, Sperling SA, Fernandez HH, Walter BL. Effects of an Inpatient Program on Medication Errors in Hospitalized People with Parkinson's Disease. Ann Neurol. 2026 Nov; 100(5):1068-1079.

View in: PubMed
Yu JRT, Sonneborn C, Hogue O, Ghosh D, Brooks A, Liao J, Fernandez HH, Shaffer S, Sperling SA, Walter BL. Establishing a framework for quality of inpatient care for Parkinson's disease: A study on inpatient medication administration. Parkinsonism Relat Disord. 2023 08; 113:105491.

View in: PubMed
Ramirez-Zamora A, Gee L, Youn Y, Shin DS, Pilitsis JG. Pallidal Deep Brain Stimulation for the Treatment of Levodopa-Responsive Juvenile Dystonia and Parkinsonism Secondary to SPG11 Mutation. JAMA Neurol. 2017 01 01; 74(1):127-128.

View in: PubMed
Abebe A, Kuang QF, Evans JJ, Sugumaran M. Mass spectrometric studies shed light on unusual oxidative transformations of 1,2-dehydro-N-acetyldopa. Rapid Commun Mass Spectrom. 2013 Aug 15; 27(15):1785-93.

View in: PubMed
Garland EM, Cesar TS, Lonce S, Ferguson MC, Robertson D. An increase in renal dopamine does not stimulate natriuresis after fava bean ingestion. Am J Clin Nutr. 2013 May; 97(5):1144-50.

View in: PubMed
Vinuela A, Hallett PJ, Reske-Nielsen C, Patterson M, Sotnikova TD, Caron MG, Gainetdinov RR, Isacson O. Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease. Brain. 2008 Dec; 131(Pt 12):3361-79.

View in: PubMed
May S, Gilman S, Sowell BB, Thomas RG, Stern MB, Colcher A, Tanner CM, Huang N, Novak P, Reich SG, Jankovic J, Ondo WG, Low PA, Sandroni P, Lipp A, Marshall FJ, Wooten F, Shults CW. Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord. 2007 Dec; 22(16):2371-7.

View in: PubMed
Henninger N, Wang Q, Okun JG, Schwab S, Krause M. Nitrous oxide promotes hyperhomocysteinemia in levodopa treated rats. Parkinsonism Relat Disord. 2007 Dec; 13(8):524-7.

View in: PubMed
Leegwater-Kim J, Waters C. Tolcapone in the management of Parkinson's disease. Expert Opin Pharmacother. 2006 Nov; 7(16):2263-70.

View in: PubMed
Tarsy D, Scollins L, Corapi K, O'Herron S, Apetauerova D, Norregaard T. Progression of Parkinson's disease following thalamic deep brain stimulation for tremor. Stereotact Funct Neurosurg. 2005; 83(5-6):222-7.

View in: PubMed

People

Explore

Similar Concepts

Top Journals